Fig. 1From: A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trialsTreatment effect estimates (chemoimmunotherapy versus chemotherapy) with continuous BMI by the method of Multivariate Fractional Polynomial Interaction with Cox proportional-hazard regression models stratified by trial for overall survival (a) and progression-free survival (b). The shaded area is the 95% CIs of the treatment effect estimated as hazard ratios (HRs) (black solid line). Vertical dotted lines mark the 5th and 95th percentile of BMI distribution of the pooled analysis cohort, at 19.8 kg/m2 and 34.7 kg/m2 respectivelyBack to article page